Clinical Trial Update: A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating response-adapted ultra-low-dose 4 Gy radiation as definitive therapy for Marginal Zone Lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: RECRUITING